ExploreDemographics, reference pathology diagnosis, Outcome (Event-free survival, Progression-free survival, Overall survival)
LHA ID: 7WF0931H2U-3
Filename:
RICOVER-60-metadata.xlsx
Format: Spreadsheet
Size: 21.4 KB
Data file type: Clinical Data
Human Diseases: No Human Disease specified
Export PNG
Creators and SubmitterViews: 3759 Downloads: 161
Created: 16th May 2019 at 15:36
Last updated: 16th May 2019 at 15:36
Last used: 2nd Feb 2025 at 14:55
TagsThis item has not yet been tagged.
AttributionsNone
Version History
Version 1 Created 16th May 2019 at 15:36 by René Hänsel
No revision comments
Related items
B-cell lymphoma is the most frequent lymphoid neoplasia accounting for one third of all lymphomas. R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone) is the current treatment standard, leading to high cure rates especially in younger patients. Although the 3-year event-free survival is about 60% even for elderly patients between 60-80 years old, the remainder of patients eventually relapse and the majority die of their disease. The German Non-Hodgkin's Lymphoma Study ...
Programme: NHL
Public web page: https://www.dshnhl.org
RICOVER-60 is a randomised study comparing 6 and 8 cycles of chemotherapy with CHOP (Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) at 14-day intervals (CHOP-14), both with or without the monoclonal anti-CD20 antibody Rituximab in patients aged 61 to 80 years with Aggressive Non-Hodgkin’s Lymphoma.
Submitter: René Hänsel
Studies: RICOVER-60
Resources: RICOVER-60 trial data, RICOVER-60 trial metadata
Demographics, reference pathology diagnosis, Outcome (Event-free survival, Progression-free survival, Overall survival)
Submitter: René Hänsel
Investigation: RICOVER-60
Resources: RICOVER-60 trial data, RICOVER-60 trial metadata
Study type: Not specified
Demographics, reference pathology diagnosis, Outcome (Event-free survival, Progression-free survival, Overall survival)
Submitter: René Hänsel
Resource type: Experimental Assay Type
Technology type: Technology Type
Investigation: RICOVER-60
Study: RICOVER-60
Projects: LHA - Leipzig Health Atlas, LIFE Adult, LIFE - Leipzig Research Center for Civilization Diseases, LIFE HNC - Head and Neck Cancer Group, LIFE Heart, MMML - Molecular mechanisms in malignant lymphoma, GLA - German Lymphoma Alliance, MMML Demonstrators - Molecular Mechanisms in Malignant Lymphomas - Demonstrators of Personalized Medicine, HaematoOpt - Individualized model-based managing of the next-cycle thrombopenia of CHOEP/CHOP treated patients based on platelets dynamics during the previous cycles, e:Med, GC-HBOC - German Consortium for Hereditary Breast and Ovarian Cancer, GC-HNPCC - German Consortium for Hereditary Non-Polyposis Colorectal Cancer, MMML-MYC-SYS, NLP4CR - Natural Language Processing for Clinical Research, Genetical Statistics and Systems Biology, SepNet - German Competence Network Sepsis, LIFE Child, HNPCC-Sys - Genomic and transcriptomic heterogeneity of colorectal tumours arising in Lynch syndrome, GGN - German Glioma Network, CAPSys - Footprints of Sepsis Framed Within Community Acquired Pneumonia in the Blood Transcriptome, CapSys - Systems Medicine of Community Acquired Pneumonia, ProstataCA, HaematoSys - Systems biology of haematopoiesis and haematopoietic neoplasia, SMITH - Smart Medical Information Technology for Healthcare, Task Force COVID-19 Leipzig, NFDI4Health, POLAR - Polypharmacy, Drug Interactions, Risks, Management of health information systems, LivSys Transfer - Transfer of the LivSys in vitro system for hepatotoxicity into application, Project Test Demonstrator, Fundus photography as tool for analysis of eyes of subjects with diabetes, Clinical Trials Leipzig, NFDI4Health - TA3 Services, STOP-NUC, SCALE-TORT, EarlyAMDRate
Institutions: Institute for Medical Informatics, Statistics and Epidemiology (IMISE)
https://orcid.org/0000-0001-8344-0658
Projects: HaematoSys - Systems biology of haematopoiesis and haematopoietic neoplasia, GLA - German Lymphoma Alliance
Web page: Not specified
